Erasca to Present at Upcoming Investor Conferences in June

Rhea-AI Summary

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, has announced its participation in two major investor conferences in June 2025:

1. Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 4 at 5:30 PM ET

2. Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11) in Miami Beach, with a fireside chat scheduled for June 10 at 2:40 PM ET

Management will participate in one-on-one investor meetings at both conferences. Live audio webcasts will be available at Erasca.com/events, with replays accessible for 30 days after each event.

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences.

Jefferies Global Healthcare Conference (June 3-5, 2025)
Location: New York, NY
Format: Fireside Chat
Date and Time: Wednesday, June 4, 5:30 pm Eastern Time

Goldman Sachs 46^th Annual Global Healthcare Conference (June 9-11, 2025)
Location: Miami Beach, FL
Format: Fireside Chat
Date and Time: Tuesday, June 10, 2:40 pm Eastern Time

A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

When and where will Erasca (ERAS) present at the Jefferies Healthcare Conference in June 2025?

Erasca will present at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 5:30 PM Eastern Time in a fireside chat format.

When is Erasca's (ERAS) presentation at the Goldman Sachs Healthcare Conference 2025?

Erasca will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach on Tuesday, June 10, 2025, at 2:40 PM Eastern Time.

How can investors access Erasca's (ERAS) conference presentations in June 2025?

Investors can access live audio webcasts of both presentations at Erasca.com/events. Archived replays will be available for 30 days following each webcast.

What type of company is Erasca (ERAS)?

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.